Activity and safety of pegylated liposomal doxorubicin, 5-fluorouracil and folinic acid in inoperable hepatocellular carcinoma: A phase II study | Zendy

Giuseppe Di Lorenzo | Zendy; Antonio Rea | Zendy; Chiara Carlomagno | Zendy; Stefano Pepe | Zendy; Giovannella Palmieri | Zendy; Roberto Labianca | Zendy; Antonio Chirianni | Zendy; Alfonso De Stefano | Zendy; Vincenzo Esposito | Zendy; Sabino De Placido | Zendy; Vincenzo Montesarchio | Zendy

Open Access

Activity and safety of pegylated liposomal doxorubicin, 5-fluorouracil and folinic acid in inoperable hepatocellular carcinoma: A phase II study

Author(s) -

Giuseppe Di Lorenzo,

Antonio Rea,

Chiara Carlomagno,

Stefano Pepe,

Giovannella Palmieri,

Roberto Labianca,

Antonio Chirianni,

Alfonso De Stefano,

Vincenzo Esposito,

Sabino De Placido,

Vincenzo Montesarchio

Publication year - 2007

Publication title -

world journal of gastroenterology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.427

H-Index - 155

eISSN - 2219-2840

pISSN - 1007-9327

DOI - 10.3748/wjg.v13.i48.6553

Subject(s) - folinic acid , medicine , hepatocellular carcinoma , fluorouracil , gastroenterology , doxorubicin , toxicity , chemotherapy , phases of clinical research , pharmacology , surgery

To improve the results of New therapeutic strategies in hepatocellular carcinoma (HCC). We have conducted a phase II study with pegylated liposomal doxorubicin (PLD), 5-fluorouracil (5FU) and folinic acid (FA).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research